An overview of coagulation disorders in cancer patients

Kvolik, Slavica; Jukič, Marko; Matijević, Marko; Marjanović, Ksenija; Glavaš‐Obrovac, Ljubica

doi:10.1016/j.suronc.2009.03.008

Cited by 90 publications

(74 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BC is the most common form of cancer in women and has a high mortality rate. One etiological factor in BC-related deaths is thrombosis (Kvolik et al 2010). Molecular and genetic studies of carcinogenesis have contributed to the development of new diagnostic and therapeutic techniques resulting in improved BC outcomes (Gunaldi et al 2015).…”

Section: Introductionmentioning

confidence: 99%

Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer

Topcu

Kavgacı

Özdemir

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer among women and a major cause of death. Signal Peptide-Cub-Epidermal growth factor domain-containing protein-1 (SCUBE1) is secreted under hypoxia and inflammatory conditions from platelet alpha granules. Its biological function is uncertain, although it may be a procoagulant substance in cancer patients. SCUBE1 is useful for identifying thrombotic diseases, including cancers and acute coronary syndromes. D-dimer reflects the relationship between coagulation activation and fibrinolysis; namely, thrombosis and D-dimer levels are closely linked. This is the first investigation of the potential diagnostic and prognostic value of SCUBE1 levels in patients with BC. Fifty patients and 33 age-matched and body mass index-matched healthy controls were enrolled. Blood samples were collected before chemotherapy regimens commenced. Serum SCUBE1 and D-dimer levels were measured before adjuvant chemotherapy and were compared to the healthy controls. SCUBE1 levels were determined using an enzyme-linked immunosorbent assay (ELISA) method. SCUBE1 and D-dimer levels were significantly higher in patients than in the controls (p = 0.03 and p < 0.001, respectively). A cut-off value of 1.55 ng/mL for SCUBE1 was associated with 62% sensitivity and 72.7% specificity and with positive predictive value of 77.5% and negative predictive value of 55.8%. Two patients with high SCUBE1 and D-dimer levels also developed pulmonary embolism. SCUBE1 may indicate hypercoagulability in patients with BC and thus help identify patients at greater risk of thrombosis and requiring anti-thrombosis treatment. SCUBE1 may also be used as an assistant test for identifying patients at risk of BC.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer

Topcu

Kavgacı

Özdemir

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…In cancer patients, hyperviscosity may be a physiological link between "Traussean's syndrome" (carcinoma-induced coagulopathy), thrombosis and metastases [18,19]. Recent investigations have found that during tumor growth, angiogenesis and the coagulation cascade, the components of the fibrinolytic system are activated, and the function of the affected organs is impaired [20][21][22]. In addition, many authors suggest that smokers bear an increased risk of thromboembolic events, as well as vascular endothelium dysfunction [23][24][25].…”

mentioning

confidence: 99%

The effect of cadmium on the coagulation and fibrinolytic system in women with uterine endometrial cancer and myoma

Nasiadek¹,

Kilanowicz²,

Daragó³

et al. 2013

International Journal of Occupational Medicine and Environmental Health

View full text Add to dashboard Cite

Objectives: Cadmium (Cd) is a persistent and widespread environmental pollutant, which may constitute a potential risk factor for hormone-dependent tumors such as endometrial cancer. The vascular endothelium is an important target of cadmium toxicity, which may interfere with the coagulation cascade and fibrinolytic system. The aim of this research was to investigate whether in female patients with uterine endometrial cancer or myoma in comparison to healthy women, the concentration of cadmium in blood affects the process of coagulation and fibrinolysis. Materials and Methods: The study group comprised 91 women: 35 healthy (A-control), 39 with uterine myoma (B) and 17 with endometrial cancer (C), in which blood cadmium concentrations (BCd), coagulation and selected fibrinolysis parameters in plasma were assayed. Results: In the women with myoma and especially in those with endometrial cancer disturbances in coagulation and fibrinolysis were detected when compared to the healthy women. In the group of women with endometrial cancer significant changes in prothrombin index, levels of fibrinogen, fibrin D-dimer and t-PA were observed. Whereas, in the patients with myoma significant changes in prothrombin time, index of vWillebrand Factor and fibrin D-dimer level were noted. Mean BCd concentrations in subsequent groups were as follows: B -0.91±0.81; C -0.78±0.45 μg Cd/l and did not differ significantly in comparison with the control group (0.86±0.35 μg Cd/l). However, in each study group smokers had approximately twice as high BCd as non-smokers. Studies also showed significant associations between BCd and fibrinogen level and thrombin time among the women with myoma and endometrial cancer, as well as in healthy women. Moreover, thrombin time significantly correlated with fibrinogen level in the women studied. Conclusions: In the patients with myoma and especially in these with endometrial cancer disturbances in coagulation and fibrinolysis parameters leading to hypercoagulability were detected. Exposure to cadmium can be one of the factors inducing these changes.

show abstract

“…Future studies with point mutations to one of the reactive glutamines will help to identify which peak is crosslinked to a faster extent. Overall, the 2D 1 H- 15 N HSQC experiments provide a direct method to quickly monitor Factor XIII's ability to crosslink reactive glutamines in fibrinogen.…”

Section: D Hsqc Nmr Experiments To Monitor Factor Xiii's Crosslinkingmentioning

confidence: 99%

“…Thrombin, glycine ethyl ester and other assay components were purchased from Sigma Aldrich. 15 N-labeled glycine ethyl ester was purchased from Cambridge Isotopes.…”

Section: Proteins and Materialsmentioning

confidence: 99%

See 1 more Smart Citation

Characterizing reactive glutamines in fibrinogen and elucidating factor XIII substrate specificity.

Mouapi¹

View full text Add to dashboard Cite

An overview of coagulation disorders in cancer patients

Cited by 90 publications

References 85 publications

Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer

Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer

The effect of cadmium on the coagulation and fibrinolytic system in women with uterine endometrial cancer and myoma

Characterizing reactive glutamines in fibrinogen and elucidating factor XIII substrate specificity.

Contact Info

Product

Resources

About